Ucenprubart Explained

Drug Name:	Ucenprubart
Synonyms:	LY3454738
Type:	mab
Legal Status:	Investigational
Cas Number:	2414559-57-0
Unii:	99OHY1NA5O

Ucenprubart (LY3454738) is a monoclonal antibody that acts as an agonist at CD200R1 and is developed by Eli Lilly and Company for atopic dermatitis and other autoimmune diseases.^{[1] [2] [3] [4]}

Notes and References

1. Metz . Martin . Maurer . Marcus . Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy? . Allergologie Select . 12 February 2021 . 5 . 89–95 . 10.5414/ALX02204E . 33615122 . 7890936 . 2512-8957.
2. Metz . Martin . Kolkhir . Pavel . Altrichter . Sabine . Siebenhaar . Frank . Levi-Schaffer . Francesca . Youngblood . Bradford A. . Church . Martin K. . Maurer . Marcus . Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases . Allergy . 22 August 2023 . 79 . 1 . 37–51 . 10.1111/all.15850. 37605867 . 261063967 . free .
3. Maurer . Marcus . Khan . David A. . Elieh Ali Komi . Daniel . Kaplan . Allen P. . Biologics for the Use in Chronic Spontaneous Urticaria: When and Which . The Journal of Allergy and Clinical Immunology: In Practice . 1 March 2021 . 9 . 3 . 1067–1078 . 10.1016/j.jaip.2020.11.043 . 33685605 . 232159087 . 2213-2198.
4. Web site: Lilly.com Eli Lilly and Company . www.lilly.com . 24 November 2023.